Days after losing Roche/Genentech as a partner for a CD40 target, Seattle Genetics signs Takeda as a partner for an antibody-drug conjugate for lymphoma.
Addex Pharmaceuticals is halting a study of its lead compound in migraine prevention because of safety concerns, likely ending the drug’s prospects for further development. The news is a stunning setback for Addex, which had planned to partner ADX10059 on the heels of positive Phase IIb data, but the company insists a chemically distinct back-up compound shows promise.
FDA's Endocrinologic and Metabolic Drugs advisory committee discusses AstraZeneca's sNDA for Crestor (rosuvastatin) for the primary prevention of cardiovascular disease, based on JUPITER study results.
Amgen pays $60 million upfront for worldwide rights to a Phase I glucokinase activator, ARRY-403, being developed by Array BioPharma in Type 2 diabetes. Under the deal, Array will complete Phase I, then Amgen will assume all development and commercialization responsibilities.
